Replies to post #187 on KalVista Pharmaceuticals (KALV)

[Jk384]

Still waaaay oversold from phase III results. Keep in mind that was not a complete failure and the patents may hold alot of value in addition to the $1.63 in NET cash. Check out this link.

http://www.streetinsider.com/dr/news.php?id=11270957